Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates
- PDF / 825,971 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 6 Downloads / 212 Views
BRIEF REPORT
Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c+ Expression in Tumor Isabelle Magalhaes
. Josefin Fernebro . Sulaf Abd Own .
Daria Glaessgen . Sara Corvigno . Mats Remberger . Jonas Mattsson . Hanna Dahlstrand Received: August 13, 2020 / Accepted: September 28, 2020 / Published online: October 14, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: Mesothelin (MSLN) is overexpressed in several tumors including ovarian cancer and is the target of current trials. There is limited and conflicting data on MSLN prognostic impact in ovarian cancer.
Isabelle Magalhaes and Josefin Fernebro contributed equally to this work as joint first authors. Jonas Mattsson and Hanna Dahlstrand also contributed equally to this work.
Electronic Supplementary Material The online version of this article (https://doi.org/10.1007/s12325020-01520-w) contains supplementary material, which is available to authorized users. I. Magalhaes D. Glaessgen S. Corvigno J. Mattsson H. Dahlstrand Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden I. Magalhaes (&) Department of Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden e-mail: [email protected] J. Fernebro Theme Cancer, Karolinska University Hospital, Stockholm, Sweden J. Fernebro S. Corvigno H. Dahlstrand Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
Methods: We performed a retrospective study on patients with high-grade serous ovarian cancer, analyzing MSLN expression by immunohistochemistry and examining the correlation of its expression to overall and progression-free survival. Correlations of expression of MSLN, CD8, and macrophage markers in different tumor compartments were also investigated. Results: Positive MSLN expression was detected in 55.1% of primary tumors and 51.5% of the metastases. MSLN expression was not correlated with survival. We observed a significant positive correlation (r = 0.34, p = 0.01) between MSLN expression in the metastatic site and CD11c expression in total tumor area and perivascular area in the primary tumor.
S. Abd Own Division of Pathology, Department of Laboratory Medicine, Karolinska University Hospital, Huddinge, Stockholm, Sweden M. Remberger Department of Medical Sciences, Uppsala University, and KFUE, Uppsala University Hospital, Uppsala, Sweden J. Mattsson Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Adv Ther (2020) 37:5023–5031
5024
Conclusion: Our results show that MSLN expression does not correlate with clinical outcome. The impact of the correlation between MSLN and CD11c? cells on immunotherapy outcome should be further explored.
for this article go to https://doi.org/10.6084/ m9.figshare.13014242.
Keywords: Immunohistochemistry; Mesothelin; Ovarian cancer
Ovarian cancer is the most leth
Data Loading...
